

ETHICS PROGRAM REVIEW FOLLOW-UP REPORT

Agency: U. S. Food and Drug Administration

Follow-up to OGE Report Number: 17-23 and 19-13F

Report No.: 20-24F

Date: May 19, 2020

UNITED STATES OFFICE OF
GOVERNMENT ETHICS


Preventing Conflicts of Interest
in the Executive Branch

As a result of its review of the Food and Drug Administration (FDA) ethics program, the Office of Government Ethics (OGE) issued nine recommendations in its May 2017 review report and closed eight recommendations in the first follow-up report in April 2019. OGE recently conducted a follow-up review to assess whether FDA has taken sufficient action to resolve the deficiencies underlying the one open recommendation in the April 2019 report. The result of the follow-up review are summarized below.

	Recommendation	Agency Action and OGE Finding	Status
1	Ensure all SGEs serving multi-year terms receive ethics training each year.	During its initial and first follow-up review, OGE determined that many of FDA's SGEs who were serving multi-year terms did not receive required annual ethics training. The Advisory Committee Oversight and Management Staff (ACOMS) was able to raise the annual ethics training completion rate from under 50% to over 97%. ACOMS has drafted Standard Operating Procedures (SOPs) with the approval of the Office of General Counsel at the Department of Health and Human Services to ensure SGEs serving multi-year terms receive annual training each year.	Closed

Based on the results of OGE's follow-up review, the last open recommendation is closed.